ExodusPoint Capital Management LP Takes Position in Cencora, Inc. (NYSE:COR)

ExodusPoint Capital Management LP acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 66,072 shares of the company's stock, valued at approximately $14,845,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of COR. United Bank boosted its holdings in shares of Cencora by 4.2% in the 3rd quarter. United Bank now owns 5,601 shares of the company's stock valued at $1,261,000 after buying an additional 225 shares during the period. Public Sector Pension Investment Board grew its holdings in shares of Cencora by 53.2% during the third quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company's stock valued at $1,555,000 after purchasing an additional 2,400 shares during the last quarter. Arete Wealth Advisors LLC raised its position in shares of Cencora by 4.9% during the 3rd quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company's stock worth $541,000 after purchasing an additional 113 shares during the period. Benjamin Edwards Inc. lifted its holdings in shares of Cencora by 1,552.8% in the 3rd quarter. Benjamin Edwards Inc. now owns 9,041 shares of the company's stock worth $2,035,000 after purchasing an additional 8,494 shares during the last quarter. Finally, Centiva Capital LP boosted its position in Cencora by 44.1% during the 3rd quarter. Centiva Capital LP now owns 6,099 shares of the company's stock valued at $1,373,000 after purchasing an additional 1,866 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on COR shares. Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $280.20.

Cencora Price Performance

NYSE COR traded down $0.86 on Wednesday, reaching $273.87. 4,241,472 shares of the stock traded hands, compared to its average volume of 1,497,578. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm's fifty day simple moving average is $259.12 and its 200 day simple moving average is $244.21. The company has a market cap of $53.11 billion, a price-to-earnings ratio of 38.96, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.